Navigation Links
Risk of death has decreased for children initially treated with dialysis for ESKD
Date:5/4/2013

In a study that included more than 20,000 patients, there was a significant decrease in the United States in mortality rates over time among children and adolescents initiating end-stage kidney disease treatment with dialysis between 1990 and 2010, according to a study in the May 8 issue of JAMA. The study is being released early online to coincide with its presentation at the Pediatric Academic Societies annual meeting.

"Individuals with end-stage kidney disease (ESKD) face a significantly shortened life expectancy. In no group of ESKD patients is the loss of potential years of life larger than in children and adolescents. Although transplant remains the treatment of choice to maximize survival, growth, and development, 75 percent of children with ESKD require treatment with dialysis prior to receiving a kidney transplant. Dialysis is therefore a life-saving therapy for children with ESKD while they await transplant. Nevertheless, all-cause mortality rates in children receiving maintenance dialysis are at least 30 times higher than the general pediatric population, with even higher relative risks in very young children," the authors write. "There have been substantial improvements in the care of children with ESKD between 1990 and 2010. However, to our knowledge, it is not known if mortality has changed over time in the United States, particularly in recent years."

Mark M. Mitsnefes, M.D., M.Sc., of Cincinnati Children's Hospital Medical Center, and colleagues conducted a study to determine if all-cause, cardiovascular, and infection-related mortality rates have changed between 1990 and 2010 among patients younger than 21 years of age with ESKD initially treated with dialysis and if changes in mortality rates over time differed by age at treatment initiation. The researchers used data from the United States Renal Data System. Children with a prior kidney transplant were excluded.

The researchers identified 23,401 children and adolescents who met study criteria. Crude mortality rates during dialysis treatment were higher among children younger than 5 years at the start of dialysis compared with those who were 5 years and older. The authors found that the all-cause mortality risk decreased progressively over calendar time for both those younger than 5 years and those 5 years and older at initiation. There was also a decrease over calendar time for cardiovascular and infection-related mortality risk among children younger than 5 years at initiation and among those 5 years and older.

"Numerous factors may have contributed to the observed reductions in mortality risk over time. Improved pre-dialysis care, advances in dialysis technology, and greater experience of clinicians may each have played a role," the authors write.

"Almost all children initiating ESKD treatment are considered eligible for transplant. However, most will require dialysis during their lifetime, either before transplant or after allograft loss. In the United States, there was a significant decrease in mortality rates over time among children and adolescents initiating ESKD treatment with dialysis between 1990 and 2010. Further research is needed to determine the specific factors responsible for this decrease."


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-934-1934
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Mild Hyperthyroidism Tied to Higher Death Risk
2. 7 Mile Bridge Death Underscores Victim Rights
3. Study Reveals L-Carnitine, Which is Found in Popular Weight Loss Supplement Liproxenol, Lowers Risk of Death From All Causes
4. No greater death risk for children admitted to emergency out-of-hours intensive care
5. Implants May Delay Breast Cancer Detection, Raise Death Risk
6. Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Responds to Doctor’s Testimony Alleging Intuitive Surgical’s Robotic Device Contributed to a Man’s Death
7. Class Action Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Who Allege Imprelis Use Caused Extensive Tree Damage and Death, Reports Wright & Schulte
8. Motorcycle Deaths Continue to Climb: Report
9. Using nitrous oxide for anesthesia doesnt increase -- and may decrease -- complications and death
10. Multiple Imprelis Lawsuits Filed by Wright & Schulte Alleging Imprelis Use Resulted in Extensive Tree Damage and Death
11. Drunk Driving Not the Only Way Alcohol Leads to Teen Deaths: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... Minneapolis MN (PRWEB) , ... February 23, 2017 , ... ... it is sending an expert sit stand solutions representative to the Minneapolis Home and ... 5. Location for the event that is garnering national attention is the Minneapolis Convention ...
(Date:2/22/2017)... ... February 22, 2017 , ... When ... new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. ... healthcare systems recently invested $51 million to purchase and renovate the 185,000 square-foot ...
(Date:2/22/2017)... ... 2017 , ... Stem cell therapy has made significant innovations ... cutting edge, in fact, the U.S. Food and Drug Administration (FDA) has yet ... outcomes in certain clinical stem cell procedures have shown that this revolutionary field ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 ... report on the global market for intraoperative imaging, ... presently valued at US$ 513.9 million. According to ... keep surging on the grounds of increasing adoption ... the field of diagnostic imaging for neurosurgeries. The ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic Devices ... over the next decade to reach approximately $8.9 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: